Jacobs Levy Equity Management’s Ovid Therapeutics OVID Stock Holding History

Jacobs Levy Equity Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200,593	Closed	-$62.6K	–	1131
2025 Q1	$62.6K	Sell	200,593 -91,108	-31%	-$56K	﹤0.01%	1055
2024 Q4	$272K	Buy	+291,701	New	+$326K	﹤0.01%	880
2024 Q2	–	Sell	-62,341	Closed	-$190K	–	1022
2024 Q1	$190K	Hold	62,341	–	–	﹤0.01%	896
2023 Q4	$201K	Hold	62,341	–	–	﹤0.01%	926
2023 Q3	$239K	Hold	62,341	–	–	﹤0.01%	904
2023 Q2	$204K	Sell	62,341 -1,400	-2%	-$4.75K	﹤0.01%	926
2023 Q1	$164K	Sell	63,741 -102,300	-62%	-$242K	﹤0.01%	915
2022 Q4	$309K	Buy	+166,041	New	+$283K	﹤0.01%	860
2021 Q2	–	Sell	-220,357	Closed	-$886K	–	1092
2021 Q1	$886K	Buy	220,357 +182,514	+482%	+$606K	0.01%	762
2020 Q4	$87K	Sell	37,843 -2,874	-7%	-$13.4K	﹤0.01%	997
2020 Q3	$234K	Buy	+40,717	New	+$272K	﹤0.01%	933
2019 Q1	–	Sell	-79,094	Closed	-$191K	–	1012
2018 Q4	$191K	Buy	79,094 +44,984	+132%	+$205K	﹤0.01%	891
2018 Q3	$193K	Buy	+34,110	New	+$259K	﹤0.01%	933

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Jacobs Levy Equity Management's OVID Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 200,593 shares — an estimated $62.6K sold.

Jacobs Levy Equity Management first reported a position in OVID in Q3 2018 and held it in 13 quarters. The position peaked at $886K in Q1 2021. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

Jacobs Levy Equity Management reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 200,593 Ovid Therapeutics shares in Q2 2025, an estimated $62.6K.
Jacobs Levy Equity Management first reported a position in Ovid Therapeutics in Q3 2018 and held it in 13 quarters.
Jacobs Levy Equity Management's Ovid Therapeutics position peaked at $886K in Q1 2021.
71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.